Pluristem Therapeutics, Inc. (NASDAQ:PSTI) saw a significant increase in short interest in September. As of September 29th, there was short interest totalling 1,230,052 shares, an increase of 47.0% from the September 15th total of 836,828 shares. Currently, 1.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,026,250 shares, the short-interest ratio is currently 1.2 days.
A hedge fund recently raised its stake in Pluristem Therapeutics stock. Renaissance Technologies LLC increased its stake in shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 9.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,553,800 shares of the biotechnology company’s stock after purchasing an additional 129,000 shares during the quarter. Renaissance Technologies LLC owned approximately 1.62% of Pluristem Therapeutics worth $1,911,000 at the end of the most recent reporting period. 4.47% of the stock is owned by institutional investors and hedge funds.
Several analysts have recently weighed in on PSTI shares. Maxim Group raised shares of Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a report on Monday, June 19th. Seaport Global Securities reaffirmed a “buy” rating and set a $5.00 price objective on shares of Pluristem Therapeutics in a report on Friday, October 6th. HC Wainwright set a $4.00 price objective on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 17th. ValuEngine raised shares of Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Finally, Zacks Investment Research lowered shares of Pluristem Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $4.13.
Shares of Pluristem Therapeutics (NASDAQ PSTI) opened at 1.71 on Friday. The stock’s 50 day moving average is $1.42 and its 200 day moving average is $1.33. Pluristem Therapeutics has a 1-year low of $1.04 and a 1-year high of $2.02. The company’s market capitalization is $166.68 million.
About Pluristem Therapeutics
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.